Electroconvulsive therapy for schizophrenia
Tharyan P
Data collection and analysis: The reviewers extracted the data
independently and analysed the data on an intention to treat basis.
Background and objectives: To determine whether electroconvulsive
therapy (ECT) results in clinically meaningful benefit with regard to global
improvement, hospitalisation, changes in mental state, behaviour and
functioning in those with schizophrenia.
Reviewers' conclusions: There is some evidence to support the use of ECT
for those with schizophrenia for short term relief of symptoms.
Electroconvulsive therapy may be advocated as an adjunct to antipsychotic
medication for those with schizophrenia who show a limited response to
medication alone but the evidence for this is not strong. In fact in spite of more
than five decades of widespread clinical use, the administration of ECT to those
with schizophrenia lacks a strong research base.
Search strategy: Electronic searches of Biological Abstracts (1982-1996),
EMBASE (1980-1996), Medline (1966-1996), PsycLIT (1974-1996) and
SCISEARCH (1996) were undertaken. The references of all identified studies
were investigated.
Selection criteria: All randomised controlled trials that compared ECT with
placebo, 'sham ECT', non-pharmacological interventions and antipsychotics for
people with schizophrenia, schizoaffective disorder or chronic mental disorder.
Main results: Less people with schizophrenia treated with ECT showed no
improvement in general functioning when compared to those given placebo in
the short term (OR 0.48 CI 99% 0.26-0.90). This effect, however, does not
last. However, ECT is less effective than antipsychotic drug treatment for those
with schizophrenia. Limited evidence exists to suggest that combining
antipsychotic drugs and ECT increases the rate and extent of clinical
improvement, in the short term, in one out of every five to six people. The
evidence for the efficacy of ECT in the medium to long term is equivocal.
Electroconvulsive therapy is also more effective than the now obsolete insulin
coma treatment.
|